Zosyn In Plastic Container is a drug owned by Baxter Healthcare Corp. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 14, 2023. Details of Zosyn In Plastic Container's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8133883 | Compositions containing piperacillin and tazobactam useful for injection |
Apr, 2023
(2 years ago) |
Expired
|
| US6900184 | Compositions containing pipercillin and tazobactam useful for injection |
Apr, 2023
(2 years ago) |
Expired
|
| US7915229 | Compositions containing piperacillin and tazobactam useful for injection |
Apr, 2023
(2 years ago) |
Expired
|
| US6207661 | Premixed formulation of piperacillin sodium and tazobactam sodium injection |
Feb, 2019
(6 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Zosyn In Plastic Container's patents.
Latest Legal Activities on Zosyn In Plastic Container's Patents
Given below is the list of recent legal activities going on the following patents of Zosyn In Plastic Container.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 15 Apr, 2024 | US8133883 |
| Maintenance Fee Reminder Mailed Critical | 30 Oct, 2023 | US8133883 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 05 Aug, 2022 | US7915229 |
| Change in Power of Attorney (May Include Associate POA) Critical | 24 Jun, 2022 | US8133883 |
| Email Notification Critical | 24 Jun, 2022 | US8133883 |
| Correspondence Address Change Critical | 23 Jun, 2022 | US8133883 |
| Email Notification Critical | 23 Jun, 2022 | US7915229 |
| Change in Power of Attorney (May Include Associate POA) Critical | 23 Jun, 2022 | US7915229 |
| Correspondence Address Change Critical | 22 Jun, 2022 | US7915229 |
| Change in Power of Attorney (May Include Associate POA) Critical | 21 Jun, 2022 | US6900184 |
US patents provide insights into the exclusivity only within the United States, but Zosyn In Plastic Container is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zosyn In Plastic Container's family patents as well as insights into ongoing legal events on those patents.
Zosyn In Plastic Container's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zosyn In Plastic Container's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 14, 2023 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zosyn In Plastic Container Generic API suppliers:
Piperacillin Sodium; Tazobactam Sodium is the generic name for the brand Zosyn In Plastic Container. 13 different companies have already filed for the generic of Zosyn In Plastic Container, with Sandoz having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zosyn In Plastic Container's generic
Alternative Brands for Zosyn In Plastic Container
Zosyn In Plastic Container which is used for treating bacterial infections., has several other brand drugs in the same treatment category and using the same active ingredient (Piperacillin Sodium; Tazobactam Sodium). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||
|---|---|---|---|---|---|---|
| Abbvie |
| |||||
| Cubist Pharms Llc |
| |||||
| Cumberland |
| |||||
| Hikma |
| |||||
| Lg Chem Ltd |
| |||||
| Pfizer |
| |||||
| Pf Prism Cv |
| |||||
| Rempex |
| |||||
| Shionogi Inc |
| |||||
| Wyeth Pharms |
| |||||
Apart from brand drugs containing the same ingredient, some generics have also been filed for Piperacillin Sodium; Tazobactam Sodium, Zosyn In Plastic Container's active ingredient. Check the complete list of approved generic manufacturers for Zosyn In Plastic Container
About Zosyn In Plastic Container
Zosyn In Plastic Container is a drug owned by Baxter Healthcare Corp. It is used for treating bacterial infections. Zosyn In Plastic Container uses Piperacillin Sodium; Tazobactam Sodium as an active ingredient. Zosyn In Plastic Container was launched by Baxter Hlthcare Corp in 1998.
Approval Date:
Zosyn In Plastic Container was approved by FDA for market use on 24 February, 1998.
Active Ingredient:
Zosyn In Plastic Container uses Piperacillin Sodium; Tazobactam Sodium as the active ingredient. Check out other Drugs and Companies using Piperacillin Sodium; Tazobactam Sodium ingredient
Treatment:
Zosyn In Plastic Container is used for treating bacterial infections.
Dosage:
Zosyn In Plastic Container is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 4GM BASE/100ML;EQ 500MG BASE/100ML | INJECTABLE | Prescription | INJECTION |
| EQ 40MG BASE/ML;EQ 5MG BASE/ML | INJECTABLE | Prescription | INJECTION |
| EQ 60MG BASE/ML;EQ 7.5MG BASE/ML | INJECTABLE | Prescription | INJECTION |